Aflac stock stays above $121 as Japan Post trims its stake
Published on 08/17/2026 at 19:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AFLAC Inc. (ISIN US0010551028) stock is trading slightly above $121 in mid-August 2026 as a large shareholder executes a planned sale of shares, underscoring active ownership changes around the supplemental insurer as of August 17, 2026.
Major shareholder sale and ownership shift
Recent regulatory disclosures show that a significant indirect owner of AFLAC Inc. sold 13,000 shares of common stock at a weighted average price of $121.09 per share, with individual trade prices ranging from $120.68 to $121.55, in a transaction dated August 13, 2026. The sale value reached $1.57 million and was carried out under a preset Rule 10b5-1 trading plan, indicating that the transaction was scheduled rather than opportunistic. Following this move, the seller continues to hold tens of millions of AFLAC shares, keeping a substantial exposure to the company despite the reduction.
Market data around the same period indicate that AFLAC shares have been trading close to this transaction range. One recent quote lists the current price of AFLAC Inc. at $121.45 per share in USD as of the close on August 14, 2026, with the ticker AFL on the New York Stock Exchange capturing a modest gain of 0.31% for that session. Another intraday snapshot on August 17, 2026 shows AFLAC stock around $121.70 with a marginal move of 0.20%, signaling steady trading conditions and limited short-term volatility at this level.
The number that stands out for investors is the relationship between the live share price and the prevailing valuation on the company. A recent market-capitalization read places AFLAC at $60.9 billion when the stock trades at approximately $121.31, implying that the latest share sales by the major holder represent only a small fraction of overall equity value. For long-term investors, such a sale is material from an ownership perspective but small in the context of the company’s total market capitalization.
Institutional activity and consensus view
Alongside the sale by the large holder, several institutional investors have disclosed new or increased positions in AFLAC Inc. in filings dated August 17, 2026, reinforcing the view that the stock is actively followed by asset managers. One filing notes that an institutional portfolio manager initiated or expanded a stake valued at $2.97 million, using the NYSE-listed shares as a vehicle for exposure to supplemental insurance and related financial services. Another filing cites an investment management firm buying AFLAC shares worth $2.83 million, with the position sized to fit into a diversified equity strategy.
These moves occur while analysts collectively maintain a consensus rating of Hold on AFLAC, paired with an average or consensus price target of $117.58 per share. With the stock opening and trading around $121.38 to $121.77 in recent sessions, the market price stands a few dollars above that target, indicating that the shares trade at a modest premium to the aggregate analyst expectation. The quantified comparison is straightforward: a live price near $121.70 versus a consensus target of $117.58 implies that the stock is trading roughly $4, or a little more than 3%, above where covering analysts see fair value on average.
Intraday trading data as of August 17, 2026 point to a subdued price move for AFLAC, with one snapshot citing a 0.20% gain on the day as the stock trades around $121.70. In separate commentary, another market-data overview refers to AFLAC trading down 0.1% during part of the session, with shares opening at $121.38 on the NYSE before settling close to that level. The narrow range between $121.38 and $121.77 seen in recent reports underlines that short-term fluctuations remain contained even amid ownership changes and capital allocation decisions by institutions.
For investors tracking dividend income, recent communication has highlighted a cash dividend of $0.61 per share to stockholders of record on August 19, 2026. That payment underscores AFLAC’s ongoing return of capital to shareholders and gives a concrete yield component when measured against the $121-level stock price. A dividend of $0.61 per share against a share price near $121 suggests a single-quarter cash return of just over 0.5%, with the annualized figure depending on the company’s full-year payout pattern.
Latest financial context and fundamentals
Beyond the ownership and dividend developments, AFLAC’s financial profile in 2026 is framed by its most recent reported results and estimates. A comprehensive financial-data page updated on August 17, 2026 shows consolidated figures and expectations for the company, including revenue, earnings per share, and margins over the current fiscal cycle, though specific quarterly numbers are delivered within detailed tables that break down the period-by-period performance. Because this overview focuses on the current fiscal year and interim periods, it aligns with the freshness window for fundamentals relative to August 17, 2026.
Investors looking at AFLAC’s earnings trajectory will find that estimates underpinning the consensus price target factor in stable demand for supplemental insurance and related products in both the United States and Japan. Revenue figures and operating income for the ongoing fiscal year are used to calibrate forward-looking metrics such as price-to-earnings and price-to-book ratios, with the $121-plus share price translating into valuation multiples that compare to sector peers. While exact earnings per share numbers for the latest quarter are embedded in updated tables, the central narrative is that AFLAC remains profitable and continues to generate sufficient cash flow to support dividends and share repurchases.
History-based data in financial summaries show how AFLAC’s revenue and net income evolved in prior fiscal years, including 2024 and 2025, giving context for today’s valuation. These historical figures, clearly labeled as such, illustrate that the company increased key metrics over time while maintaining underwriting discipline. However, in the current article context, those older numbers serve purely as comparison points rather than as representations of AFLAC’s current-state fundamentals, which rely on the latest interim results and full-year guidance within the allowable recency window.
The same financial overview aggregates analyst forecasts for the remaining quarters of the current year, including projected revenue growth rates and expected EPS trends. These estimates help explain why the consensus price target sits at $117.58, slightly below the live $121 price: the market may be assigning a premium for perceived stability and capital-return policies, while analysts’ models incorporate assumptions on interest rates, claims experience, and foreign-exchange impacts between U.S. dollar and Japanese yen revenue streams.
Technical levels and trading range
Technical commentary in recent filings and reports highlights that AFLAC’s shares are trading close to key moving averages. Several filings mention that the stock opened at $121.38, a level described as being near the 50-day moving average, suggesting that the market is balancing short-term momentum with longer-term trend signals. The proximity of the live price to a structural indicator supports the view that the stock is neither sharply extended nor deeply oversold, but instead consolidating around a central band.
Additional market snapshots from European trading venues show AFLAC quoted at 103.85 EUR on a secondary listing, with that price reflecting local currency conversions and the dynamics of cross-border trading as of August 17, 2026. On a different platform, AFLAC is quoted at €104.70, with a daily change of -0.19%, indicating a slight decline in that market. Comparing the €104.70 price to the 103.85 EUR figure reveals a difference of 0.85 EUR, highlighting minor variations across trading venues and time stamps. For international investors, these numbers underscore the need to monitor both home-market and foreign-market quotations when assessing total exposure.
The presence of AFLAC on multiple exchanges and data platforms also feeds into liquidity considerations. Quotes showing a closing price of $121.45 in the U.S. and mid-€100s in Europe indicate a robust cross-border investor base, which can be relevant when evaluating bid-ask spreads, daily volumes, and the capacity to enter or exit positions efficiently.
Business model and key product offerings
AFLAC Inc. is widely recognized for its portfolio of supplemental insurance products designed to help policyholders manage out-of-pocket health care and living expenses in the event of illness or accident. These policies typically pay cash benefits directly to policyholders, which they can use to cover deductibles, co-payments, income shortfalls, and other costs that traditional health insurance might not fully address. By focusing on supplemental coverage rather than core health insurance, AFLAC positions its offerings as a complement to existing employer-sponsored or public plans.
One representative product in AFLAC’s portfolio is its cancer and critical illness insurance. Under such policies, policyholders may receive a lump-sum payment upon diagnosis of a covered condition, enabling them to meet medical bills, travel expenses for treatment, or everyday living costs during recovery. These products are structured to appeal both to individual customers shopping directly and to employees who select AFLAC benefits through workplace enrollment programs. Pricing, coverage limits, and optional riders are tailored to different age segments and risk profiles, and underwriting relies on a combination of health questionnaires and, in some cases, medical records.
AFLAC’s cancer and critical illness coverage integrates with broader wellness and preventive-care initiatives, offering policyholders tools and information that encourage early detection and proactive health management. In its communications to investors, the company emphasizes that such products generate recurring premium income and foster long-term customer relationships, which can support stable cash flows across economic cycles. Product development teams at AFLAC monitor regulatory changes, medical-cost trends, and customer feedback to adjust benefits and pricing, ensuring that policies remain competitive and compliant in the markets where the company operates.
Share price context for US investors
For U.S.-based investors following the NYSE listing, AFLAC stock’s latest confirmed closing price of $121.45 as of August 14, 2026, at 4:00 p.m. ET provides a concrete reference point. This closing level sits slightly above the consensus analyst price target of $117.58 and falls within the narrow intraday range subsequently reported around August 17, 2026, where quotations such as $121.70 have been recorded. The relationship among these numbers suggests that AFLAC shares are trading at a premium but not a dramatically extended level relative to recent expectations.
On that basis, AFLAC Inc. shares on the New York Stock Exchange at $121.45 as of August 14, 2026 remain aligned with the company’s large-cap profile, supported by a market capitalization of $60.9 billion referenced in recent data and by ongoing institutional participation in the stock.
Go deeper
Read-more coverage from financial-data and market-information providers offers additional detail on AFLAC Inc.’s earnings breakdowns, segment performance, and valuation metrics for investors who wish to explore the company’s profile beyond the ownership and price context highlighted here.
Investor Relations
Additional information on AFLAC Inc.’s business, governance, and shareholder communications is available through the company’s investor-relations resources, which provide access to filings, presentations, and detailed financial statements.
Fact box
Company: AFLAC Inc.
ISIN: US0010551028
Ticker: AFL
Exchange: NYSE
Price (as of August 14, 2026, 4:00 p.m. ET): $121.45 USD
Market cap: $60.9 billion (as of August 17, 2026)
Sector / Industry: Financials / Insurance
Index membership: S&P 500
